Kymera completes KT-474 Phase 1 Part C dosing; webcast Dec 14 for data

Kymera Therapeutics, Inc.

Completed dosing in Part C of KT-474 Phase 1 trial for hidradenitis suppurativa and atopic dermatitis.
Will hold investor webcast on December 14, 2022 to present clinical data from KT-474 and oncology pipeline.
KT-333 (STAT3 degrader) and KT-413 (IRAKIMiD) continuing Phase 1 dose escalation.
KT-253 (MDM2 degrader) has completed IND enabling studies; expects to file IND by year-end 2022.
Collaboration with Sanofi for IRAK4 degrader development outside oncology/immune-oncology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.